Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis

Psychiatry Research

Volumn 187, Issue 1-2, 2011, Pages 42-48

  Stauffer, Virginia L ^a   Case, Michael ^a   Kinon, Bruce J ^a   Conley, Robert ^a   Ascher Svanum, Haya ^a   Kollack Walker, Sara ^a   Kane, John ^b   McEvoy, Joseph ^c   Lieberman, Jeffrey ^d,e  

^a ELI LILLY AND COMPANY   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d New York Presbyterian Columbia University Medical Center   (United States)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Haloperidol; Olanzapine; Prediction models; Schizophrenia

Indexed keywords

HALOPERIDOL; OLANZAPINE;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HALOPERIDOL; HUMANS; INTERNATIONAL COOPERATION; MALE; MENTAL DISORDERS; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS; TREATMENT OUTCOME; WEIGHT GAIN; YOUNG ADULT;

EID: 79953079202     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2010.11.017     Document Type: Article

References (29)

1. Agid O., Kapur S., Arenovich T., Zipursky R.B. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Archives of General Psychiatry 2003, 60:1228-1235.
2. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. The American Journal of Psychiatry 2005, 162:441-449.
3. Ascher-Svanum H., Nyhuis A.W., Faries D.E., Kinon B.J., Baker R.W., Shekhar A. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophrenia Bulletin 2008, 34:1163-1171.
4. Barnes T.R. A rating scale for drug-induced akathisia. The British Journal of Psychiatry 1989, 154:672-676.
5. Basson B.R., Kinon B.J., Taylor C.C., Szymanski K.A., Gilmore J.A., Tollefson G.D. Factors influencing weight change in patients with schizophrenia treated with olanzapine versus haloperidol or risperidone. The Journal of Clinical Psychiatry 2001, 62:231-238.
6. Correll C.U., Malhotra A.K., Kaushik S., McMeniman M., Kane J.M. Early prediction of antipsychotic response in schizophrenia. The American Journal of Psychiatry 2003, 160:2063-2065.
7. DeLisi L.E., Sakuma M., Tew W., Kushner M., Hoff A.L., Grimson R. Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Research 1997, 74:129-140.
8. Derks E.M., Fleischhacker W.W., Boter H., Peuskens J., Kahn R.S., EUFEST Study Group Antipsychotic drug treatment in first-episode psychosis: should patients be switched to a different antipsychotic drug after 2, 4, or 6weeks of nonresponse?. Journal of Clinical Psycopharmacology 2010, 30:176-180.
9. Guy W. Clinical global impression. ECDEU assessment manual for psychopharmacology, revised 1976, 125-126. National Institute of Mental Health, Rockville, MD. W. Guy (Ed.).
10. Ho B.C., Andreasen N.C., Nopoulos P., Arndt S., Magnotta V., Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Archives of General Psychiatry 2003, 60:585-594.
11. Kapur S., Arenovich T., Agid O., Zipursky R., Lindborg S., Jones B. Evidence for onset of antipsychotic effects within the first 24hours of treatment. The American Journal of Psychiatry 2005, 162:939-946.
12. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13:261-276.
13. Kinon B.J., Chen L., Ascher-Svanum H., Kollack-Walker S., Sniadecki J.L., Kane J.M. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophrenia Research 2008, 102:230-240.
14. Kinon B.J., Chen L., Ascher-Svanum H., Stauffer V.L., Kollack-Walker S., Zhou W., Kapur S., Kane J.M. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 2010, 35:581-590.
15. Lemon S.C., Roy J., Clark M.A., Friedmann P.D., Rakowski W. Classification and regression tree analysis in public health: methodological review and comparison with logistic regression. Annals of Behavioral Medicine 2003, 26:172-181.
16. Leucht S., Busch R., Hamann J., Kissling W., Kane J.M. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biological Psychiatry 2005, 57:1543-1549.
17. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., Engel R.R. What does the PANSS mean?. Schizophrenia Research 2005, 79:231-238.
18. Leucht S., Busch R., Kissling W., Kane J.M. Early prediction of antipsychotic nonresponse among patients with schizophrenia. The Journal of Clinical Psychiatry 2007, 68:352-360.
19. Leucht S., Davis J.M., Engel R.R., Kane J.M., Wagenpfeil S. Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology 2007, 32:1903-1910.
20. Lieberman J., Chakos M., Wu H., Alvir J., Hoffman E., Robinson D., Bilder R. Longitudinal study of brain morphology in first episode schizophrenia. Biological Psychiatry 2001, 49:487-499.
21. Lieberman J.A., Tollefson G., Tohen M., Green A.I., Gur R.E., Kahn R., McEvoy J., Perkins D., Sharma T., Zipursky R., Wei H., Hamer R.M., HGDH Study Group Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. The American Journal of Psychiatry 2003, 160:1396-1404.
22. May P.R., Van Putten T., Yale C. Predicting outcome of antipsychotic drug treatment from early response. The American Journal of Psychiatry 1980, 137:1088-1089.
23. McCarley R.W., Wible C.G., Frumin M., Hirayasu Y., Levitt J.J., Fischer I.A., Shenton M.E. MRI anatomy of schizophrenia. Biological Psychiatry 1999, 45:1099-1119.
24. McGlashan T.H., Fenton W.S. Subtype progression and pathophysiologic deterioration in early schizophrenia. Schizophrenia Bulletin 1993, 19:71-84.
25. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. The British Journal of Psychiatry 1979, 134:382-389.
26. Obermeier M., Mayr A., Schennach-Wolff R., Seemüller F., Möller H.J., Riedel M. Should the PANSS be rescaled?. Schizophrenia Bulletin 2010, 36:455-460.
27. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica. Supplementum 1970, 212:11-19.
28. Siris S.G. Depression in schizophrenia: perspective in the era of "atypical" antipsychotic agents. The American Journal of Psychiatry 2000, 157:1379-1389.
29. Zipursky R.B., Hongbin G.U., Green A.I., Perkins D.O., Tohen M.F., McEvoy J.P., Strakowski S.M., Sharma T., Kahn R.S., Gur R.E., Tollefson G.D., Lieberman J.A. Course and predictors of weight gain in people with first-episode psychosis treatedwith olanzapine or haloperidol. The British Journal of Psychiatry 2005, 187:537-543.